Literature DB >> 28345458

Proteasome expression and activity in cancer and cancer stem cells.

Ioannis A Voutsadakis1,2.   

Abstract

Proteasome is a multi-protein organelle that participates in cellular proteostasis by destroying damaged or short-lived proteins in an organized manner guided by the ubiquitination signal. By being in a central place in the cellular protein complement homeostasis, proteasome is involved in virtually all cell processes including decisions on cell survival or death, cell cycle, and differentiation. These processes are important also in cancer, and thus, the proteasome is an important regulator of carcinogenesis. Cancers include a variety of cells which, according to the cancer stem cell theory, descend from a small percentage of cancer stem cells, alternatively termed tumor-initiating cells. These cells constitute the subsets that have the ability to propagate the whole variety of cancer and repopulate tumors after cytostatic therapies. Proteasome plays a role in cellular processes in cancer stem cells, but it has been found to have a decreased function in them compared to the rest of cancer cells. This article will discuss the transcriptional regulation of proteasome sub-unit proteins in cancer and in particular cancer stem cells and the relationship of the proteasome with the pluripotency that is the defining characteristic of stem cells. Therapeutic opportunities that present from the understanding of the proteasome role will also be discussed.

Entities:  

Keywords:  19S; 20S; Proteasome; cancer stem cells; carcinogenesis; pluripotency; sub-units

Mesh:

Substances:

Year:  2017        PMID: 28345458     DOI: 10.1177/1010428317692248

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  24 in total

1.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

2.  Fascin protein stabilization by miR-146a implicated in the process of a chronic inflammation-related colon carcinogenesis model.

Authors:  Yusuke Kanda; Tokuichi Kawaguchi; Mitsuhiko Osaki; Kunishige Onuma; Takahiro Ochiya; Tomoyuki Kitagawa; Futoshi Okada
Journal:  Inflamm Res       Date:  2018-07-28       Impact factor: 4.575

3.  USP11 Enhances TGFβ-Induced Epithelial-Mesenchymal Plasticity and Human Breast Cancer Metastasis.

Authors:  Daniel A Garcia; Christina Baek; M Valeria Estrada; Tiffani Tysl; Eric J Bennett; Jing Yang; John T Chang
Journal:  Mol Cancer Res       Date:  2018-05-03       Impact factor: 5.852

4.  Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.

Authors:  László Bányai; Maria Trexler; Krisztina Kerekes; Orsolya Csuka; László Patthy
Journal:  Elife       Date:  2021-01-11       Impact factor: 8.140

5.  Block Design with Common Reference Samples Enables Robust Large-Scale Label-Free Quantitative Proteome Profiling.

Authors:  Tong Zhang; Matthew J Gaffrey; Matthew E Monroe; Dennis G Thomas; Karl K Weitz; Paul D Piehowski; Vladislav A Petyuk; Ronald J Moore; Brian D Thrall; Wei-Jun Qian
Journal:  J Proteome Res       Date:  2020-05-22       Impact factor: 4.466

6.  Integrated genomic analysis of proteasome alterations across 11,057 patients with 33 cancer types: clinically relevant outcomes in framework of 3P medicine.

Authors:  Na Li; Xianquan Zhan
Journal:  EPMA J       Date:  2021-09-30       Impact factor: 6.543

7.  High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities.

Authors:  Ioannis A Voutsadakis
Journal:  Target Oncol       Date:  2020-02       Impact factor: 4.864

Review 8.  Expression and function of immune ligand-receptor pairs in NK cells and cancer stem cells: therapeutic implications.

Authors:  Ioannis A Voutsadakis
Journal:  Cell Oncol (Dordr)       Date:  2018-02-22       Impact factor: 6.730

9.  Pharmacological or TRIB3-Mediated Suppression of ATF4 Transcriptional Activity Promotes Hepatoma Cell Resistance to Proteasome Inhibitor Bortezomib.

Authors:  Tiit Örd; Daima Örd; Minna U Kaikkonen; Tõnis Örd
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

10.  Nucleolar Proteome Analysis and Proteasomal Activity Assays Reveal a Link between Nucleolus and 26S Proteasome in A. thaliana.

Authors:  Charlotte Montacié; Nathalie Durut; Alison Opsomer; Denise Palm; Pascale Comella; Claire Picart; Marie-Christine Carpentier; Frederic Pontvianne; Christine Carapito; Enrico Schleiff; Julio Sáez-Vásquez
Journal:  Front Plant Sci       Date:  2017-10-20       Impact factor: 5.753

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.